Dr. Brittney Harrington is an emerging leader in ovarian cancer research, with over 10 years of experience in identifying and investigating therapeutic targets for the disease. After completing her PhD at the University of Queensland in 2016, Dr. Harrington did her postdoctoral research at the prestigious National Cancer Institute in the United States. Dr. Harrington returned to Australia in late 2023, leading research on predictive gene expression signatures for chemotherapy response in ovarian cancers, in Professor Susan Ramus’ Molecular Oncology research group at UNSW. Concurrently, Dr. Harrington leads an independent research project investigating metabolic enzyme activity in the ovarian tumour microenvironment in advanced pre-clinical models.
Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM, 2024, 'Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer', Cancer Gene Therapy, 31, pp. 721 - 735, http://dx.doi.org/10.1038/s41417-024-00748-w
Journal articles | 2023
Harrington BS; Kamdar R; Ning F; Korrapati S; Caminear MW; Hernandez LF; Butcher D; Edmondson EF; Traficante N; Hendley J; Gough M; Rogers R; Lourie R; Shetty J; Tran B; Elloumi F; Abdelmaksoud A; Nag ML; Mazan-Mamczarz K; House CD; Hooper JD; Annunziata CM, 2023, 'UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer', Journal of Experimental and Clinical Cancer Research, 42, http://dx.doi.org/10.1186/s13046-023-02820-z
Journal articles | 2023
Kamdar RD; Harrington BS; Attar E; Korrapati S; Shetty J; Zhao Y; Tran B; Wong N; House CD; Annunziata CM, 2023, 'NF-κB Signaling Modulates miR-452-5p and miR-335-5p Expression to Functionally Decrease Epithelial Ovarian Cancer Progression in Tumor-Initiating Cells', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms24097826
Journal articles | 2023
Kamdar RD; Harrington BS; Korrapati S; Attar E; Wong N; House CD; Annunziata CM, 2023, 'NF-κB classical and alternative signaling differentially regulate miRNA expression in ovarian cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.AM2023-3781
Journal articles | 2023
Kudo K; Harrington BS; Ning F; Kamdar R; Shibuya Y; Korrapati S; Fergusson M; Kucera C; Massimo F; Annunziata CM, 2023, 'New therapeutic strategies suppressing NAD plus and ATP production in cancer metabolism specific to 3D cultured ovarian cancer cells', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.AM2023-488
Journal articles | 2022
Caminear MW; Harrington BS; Kamdar RD; Kruhlak MJ; Annunziata CM, 2022, 'Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells', Frontiers in Oncology, 12, http://dx.doi.org/10.3389/fonc.2022.762820
Journal articles | 2021
Kryza T; Khan T; Lovell S; Harrington BS; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala JK; Dreyer T; Magdolen V; Reuning U; He Y; Tate EW; Hooper JD, 2021, 'Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1', Nature Chemical Biology, 17, pp. 776 - 783, http://dx.doi.org/10.1038/s41589-021-00783-w
Journal articles | 2020
Harrington BS; Annunziata CM, 2020, 'Drugs targeting ovarian cancer tumor-initiating cells enhance oxidative stress and prevent disease recurrence', CANCER RESEARCH, 80, http://dx.doi.org/10.1158/1538-7445.AM2020-3582
Journal articles | 2020
Harrington BS; He Y; Khan T; Puttick S; Conroy PJ; Kryza T; Cuda T; Sokolowski KA; Tse BWC; Robbins KK; Arachchige BJ; Stehbens SJ; Pollock PM; Reed S; Weroha SJ; Haluska P; Salomon C; Lourie R; Perrin LC; Law RHP; Whisstock JC; Hooper JD, 2020, 'Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer', Theranostics, 10, pp. 2095 - 2114, http://dx.doi.org/10.7150/thno.30736
Journal articles | 2020
Harrington BS; Ozaki MK; Caminear MW; Hernandez LF; Jordan E; Kalinowski NJ; Goldlust IS; Guha R; Ferrer M; Thomas C; Shetty J; Tran B; Wong N; House CD; Annunziata CM, 2020, 'Drugs targeting tumor-initiating cells prolong survival in a post-surgery, post-chemotherapy ovarian cancer relapse model', Cancers, 12, pp. 1 - 21, http://dx.doi.org/10.3390/cancers12061645
Journal articles | 2020
He Y; Davies CM; Harrington BS; Hellmers L; Sheng Y; Broomfield A; McGann T; Bastick K; Zhong L; Wu A; Maresh G; McChesney S; Yau Wong K; Adams MN; Sullivan RC; Palmer JS; Burke LJ; Ewing AD; Zhang X; Margolin D; Li L; Lourie R; Matsika A; Srinivasan B; McGuckin MA; Lumley JW; Hooper JD, 2020, 'CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin', Oncogene, 39, pp. 219 - 233, http://dx.doi.org/10.1038/s41388-019-0983-3
Journal articles | 2020
Khan T; He Y; Kryza T; Harrington BS; Gunter JH; Sullivan MA; Cuda T; Rogers R; Davies CM; Broomfield A; Gough M; Wu AC; McGann T; Weroha SJ; Haluska P; Forbes JM; Armes JE; Barry SC; Coward JI; Jagasia N; Chetty N; Snell CE; Lourie R; Perrin LC; Hooper JD, 2020, 'Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma', Cancers, 12, http://dx.doi.org/10.3390/cancers12040869
He Y; Reid JC; He H; Harrington BS; Finlayson B; Khan T; Hooper JD, 2018, 'Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1', Biological Chemistry, 399, pp. 1091 - 1097, http://dx.doi.org/10.1515/hsz-2017-0308
Journal articles | 2017
Chen Y; Harrington BS; Lau KCN; Burke LJ; He Y; Iconomou M; Palmer JS; Meade B; Lumley JW; Hooper JD, 2017, 'Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens', Journal of Pharmaceutical and Biomedical Analysis, 139, pp. 65 - 72, http://dx.doi.org/10.1016/j.jpba.2017.02.047
Journal articles | 2017
Oancea I; Movva R; Das I; Aguirre De Cárcer D; Schreiber V; Yang Y; Purdon A; Harrington B; Proctor M; Wang R; Sheng Y; Lobb M; Lourie R; Cuív PO; Duley JA; Begun J; Florin THJ, 2017, 'Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism', Gut, 66, pp. 59 - 69, http://dx.doi.org/10.1136/gutjnl-2015-310874
Journal articles | 2016
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; De Fazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD, 2016, 'Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer', British Journal of Cancer, 114, pp. 417 - 426, http://dx.doi.org/10.1038/bjc.2015.471
Journal articles | 2016
He Y; Harrington BS; Hooper JD, 2016, 'New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways', Oncoscience, 3, pp. 5 - 8, http://dx.doi.org/10.18632/oncoscience.286
Wu AC; He Y; Broomfield A; Paatan NJ; Harrington BS; Tseng HW; Beaven EA; Kiernan DM; Swindle P; Clubb AB; Levesque JP; Winkler IG; Ling MT; Srinivasan B; Hooper JD; Pettit AR, 2016, 'CD169+ macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer', Journal of Pathology, 239, pp. 218 - 230, http://dx.doi.org/10.1002/path.4718
Journal articles | 2015
Adams MN; Harrington BS; He Y; Davies CM; Wallace SJ; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD, 2015, 'EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface', Oncogene, 34, pp. 1375 - 1383, http://dx.doi.org/10.1038/onc.2014.88
Journal articles | 2015
Pinder A; Loo D; Harrington B; Oakes V; Hill MM; Gabrielli B, 2015, 'JIP4 is a PLK1 binding protein that regulates p38MAPK activity in G2 phase', Cellular Signalling, 27, pp. 2296 - 2303, http://dx.doi.org/10.1016/j.cellsig.2015.08.009
Journal articles | 2014
Dong Y; Harrington BS; Adams MN; Wortmann A; Stephenson SA; Lisle J; Herington A; Hooper JD; Clements JA, 2014, 'Activation of membrane-bound proteins and receptor systems: A link between tissue kallikrein and the KLK-related peptidases', Biological Chemistry, 395, pp. 977 - 990, http://dx.doi.org/10.1515/hsz-2014-0147
Journal articles | 2014
Oakes V; Wang W; Harrington B; Lee WJ; Beamish H; Chia KM; Pinder A; Goto H; Inagaki M; Pavey S; Gabrielli B, 2014, 'Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle', Cell Cycle, 13, pp. 3302 - 3311, http://dx.doi.org/10.4161/15384101.2014.949111
Preprints | 2022
Harrington B; Kamdar R; Ning F; Korrapati S; Caminear M; Hernandez L; Butcher D; Edmondson E; Traficante N; Australian Ovarian Cancer Study Group ; Gough M; Rogers R; Lourie R; Shetty J; Tran B; Elloumi F; Abdelmaksoud A; Lal Nag M; Mazan-Mamczarz K; House C; Hooper J; Bowtell D; Annunziata C, 2022, UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer, http://dx.doi.org/10.1101/2022.10.07.509566
Preprints | 2020
Kryza T; Khan T; Lovell S; Harrington B; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala J; Dreyer T; Magdolen V; Reuning U; He Y; Tate E; Hooper JD, 2020, Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1, http://dx.doi.org/10.21203/rs.3.rs-92391/v1
